Phase I clinical trial of a novel procaspase-3 activator SM-1 with temozolomide in recurrent high-grade gliomas

Objective: Despite a standard of care, the mortality of recurrent high-grade gliomas (HGGs) remains high. SM-1 is a novel molecular activator that has shown to target procaspase-3, which is overexpressed in HGGs. A phase I clinical trial was conducted to evaluate the safety, pharmacokinetics, and pr...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Mengqian Huang, Zhuang Kang, Shenglan Li, Botao Zhang, Yantao Xiao, Shangwei Li, Wenbin Li
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Elsevier 2025-03-01
סדרה:	Neoplasia: An International Journal for Oncology Research
נושאים:	Glioblastoma Procaspase-3 High-grade glioma Temozolomide Targeted therapy
גישה מקוונת:	http://www.sciencedirect.com/science/article/pii/S147655862500020X
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!